Sutro Biopharma STRO 深 沪
等待开盘 07-06 09:30:00 美东时间
30.43
+0.190
+0.63%
华盛通- 最 高32.12
- 今 开30.58
- 成交量 52.49万股
- 最 低 30.13
- 昨 收 30.24
- 总市值 5.04亿
- 52周最高 43.85
- 市盈率 静 --
- 换手率 3.17%
- 52周最低 7.211
- 委 比 -36.51%
- 总股本 1657.04万
- 历史最高 283.00
- 量 比 0.60
- 振 幅 6.58%
- 历史最低 5.231
- 每 手 1
- 风险率 9.69%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 甲骨文绩后分歧大！5家上调，2家下调；Navan、Hinge Health、凯西通用获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从6美元升至10美元；Ascendiant Capital：维持Aytu BioPharma"买入"评级，目标价从14美元升至14.5美元
06-12 11:32
Truist Securities Assumes Sutro Biopharma at Buy, Announces Price Target of $50
Truist Securities analyst Supawat Thongthip assumes Sutro Biopharma (NASDAQ:STRO) with a Buy rating and announces Price Target of $50.
06-11 20:46
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Barclays Initiates Coverage On Sutro Biopharma with Overweight Rating, Announces Price Target of $56
Barclays analyst Lukas Shumway initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Overweight rating and announces Price Target of $56.
05-28 21:40
Why Agilysys Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
Agilysys Inc (AGYS) shares rose in pre-market trading after reporting better-than-expected financial results and issuing positive sales guidance. Other notable gainers and losers in pre-market trading include AMST, HAO, MTVA, ONCO, SDA, PIII, VRAX, PURR, BKKT, WOK, BTM, and UBXG.
05-19 16:47
美股大行评级 | 应用材料获17家大行集体上调目标价；Bitdeer 、Forgent 、嘉信理财、Viking等获多家大行上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从11美元升至12美元；Ladenburg Thalmann：维持Usio"买入"评级，目标价从5.75美元升至6.25美元
05-18 11:48
HC Wainwright & Co. Maintains Buy on Sutro Biopharma, Raises Price Target to $50
HC Wainwright & Co. analyst Andres Y. Maldonado maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $28 to $50.
05-15 18:34
Sutro Biopharma Q1 EPS $(2.94) Beats $(3.77) Estimate, Sales $14.523M Beat $8.079M Estimate
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(2.94) per share which beat the analyst consensus estimate of $(3.77) by 22.02 percent. This is a 67.69 percent increase over losses of $(9.10) per share from
05-15 04:45
美股大行评级 | 潜在涨幅128.69%！Immunic获HC Wainwright & Co.升目标价至22美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immunic"买入"评级，目标价从5美元升至22美元；花旗：维持ServiceNow"买入"评级，目标价从154美元升至158美元
05-01 10:49
Mizuho Initiates Coverage On Sutro Biopharma with Outperform Rating, Announces Price Target of $50
Mizuho analyst Salim Syed initiates coverage on Sutro Biopharma (NASDAQ:STRO) with a Outperform rating and announces Price Target of $50.
04-30 17:38
